Drug | Page 234 of 280 | SpiritIndia.com

Health :: Racial discrimination a key factor in African-American health disparities

The experience of racial discrimination may be a key factor in explaining why African Americans have higher rates of obesity and suffer at higher rates from such diseases as diabetes and cardiovascular disorders, according to UCLA researchers. Repeated responses to such discrimination — which include elevated blood pressure and heart rate — can cause enormous stress on a person’s mental and physical health, according to research scheduled to be published in Volume 58 of the Annual Review of Psychology.

Cancer :: Saving salivary glands from the collateral damage of radiation therapy

Researchers have shown that targeted overexpression of heat shock protein 25 prevents radiation-induced damage to salivary glands, a common consequence of treatment for head and neck cancer. The related report by Lee et al., “Radioprotective effect of HSP25 on submandibular glands of rats,” appears in the November issue of The American Journal of Pathology.

Hypertension :: Results of TROPHY study on hypertension are misleading

There may be as many as 70 million Americans with prehypertension. If these people can be treated pharmacologically to avoid or delay progression to clinical hypertension, there would be significant benefits to them and the overall health of the population. The recent TROPHY study seems to lead to that conclusion. However, two editorials published in the November issue of the American Journal of Hypertension emphatically argue that the study is flawed and the conclusions reached are misleading.

Schizophrenia :: Neurophysiological link between cannabis use and schizophrenia

Researchers have found altered neural synchronization in people who smoke cannabis, providing evidence to support the link between the use of this drug and schizophrenia.

Prostate Cancer :: Hong Kong scientists identify cancer-blocking protein

Scientists in Hong Kong have identified a protein that can help suppress the growth of prostate cancer cells, the third most common cancer in men worldwide, and the finding might pave the way for the making of a new drug but not so soon.

Asthma :: Bronchial thermoplasty reduces asthma attacks

The removal of muscle tissue in the hyperactive airways of asthma patients by exposing the tissue to heat reduces disease exacerbations and significantly improves the patients’ quality of life.

Diabetes :: EC approves use of insulin drug “NovoRapid”

There is new hope of succour for women suffering from pregnancy diabetes with the European Commission (EC) approving the use of insulin drug ”NovolRapid,” as the first modern insulin that has a label stating can be used in pregnancy.

Eyes :: Using Decorative Contact Lenses without Consulting Eye Care Professional?

This Halloween season, the U.S. Food and Drug Administration (FDA) is again warning consumers about the serious risks of using decorative contact lenses without the appropriate involvement of an eye care professional. These contact lenses, sometimes called Plano or non-corrective lenses, do not correct vision and are intended solely to change the appearance of the eye, but carry serious risks, including permanent eye injury that may lead to blindness.

Tuberculosis :: Drug Resistant Tuberculosis an emerging threat

Strains of tuberculosis (TB) that are resistant to both first-line and second-line drugs could threaten the success of not only tuberculosis programs, but also HIV treatment programs worldwide, according to an article published online this week in The Lancet. The report details a study by a team of investigators from the United States and South Africa, who found that highly resistant strains of TB were more common than previously thought in a rural area of KwaZulu Natal, South Africa, and were associated with high death rates in patients with HIV infection. TB accounts for approximately 1.7 million deaths worldwide, each year, and is the leading cause of death in HIV-infected patients in low-income countries.

ADHD :: Daytrana, methylphenidate transdermal system provides individualized ADHD symptom management

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that its Attention Deficit Hyperactivity Disorder (ADHD) patch, DAYTRANA tm (methylphenidate transdermal system), has significant efficacy in reducing the symptoms of ADHD in children aged 6 to 12 years, even when the ADHD patch is taken off earlier than the recommended nine hours. The ability to remove the patch earlier than the recommended nine-hour wear time allows physicians the opportunity to manage the potential for late-day side effects, such as lack of appetite or difficulty sleeping. These phase IIIb clinical trial results were reported today at a major scientific and educational meeting of child and adolescent psychiatrists in San Diego, Calif.